Nordea Investment Management AB Has $541.33 Million Holdings in Becton, Dickinson and Company $BDX

Nordea Investment Management AB cut its stake in Becton, Dickinson and Company (NYSE:BDX) by 14.2% in the fourth quarter, Holdings Channel.com reports. The firm owned 2,773,058 shares of the medical instruments supplier’s stock after selling 458,456 shares during the period. Nordea Investment Management AB’s holdings in Becton, Dickinson and Company were worth $541,329,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Other institutional investors and hedge funds also recently made changes to their positions in the company. Value Partners Investments Inc. raised its position in shares of Becton, Dickinson and Company by 18.0% during the fourth quarter. Value Partners Investments Inc. now owns 5,600 shares of the medical instruments supplier’s stock valued at $1,088,000 after buying an additional 855 shares during the last quarter. Northside Capital Management LLC lifted its stake in shares of Becton, Dickinson and Company by 0.6% in the fourth quarter. Northside Capital Management LLC now owns 53,328 shares of the medical instruments supplier’s stock valued at $10,349,000 after buying an additional 316 shares during the period. Permanent Capital Management LP acquired a new stake in Becton, Dickinson and Company during the fourth quarter worth about $909,000. Sagespring Wealth Partners LLC increased its stake in Becton, Dickinson and Company by 23.3% during the fourth quarter. Sagespring Wealth Partners LLC now owns 5,707 shares of the medical instruments supplier’s stock valued at $1,108,000 after acquiring an additional 1,079 shares during the period. Finally, Everhart Financial Group Inc. increased its stake in Becton, Dickinson and Company by 32.6% during the fourth quarter. Everhart Financial Group Inc. now owns 1,424 shares of the medical instruments supplier’s stock valued at $276,000 after acquiring an additional 350 shares during the period. Institutional investors own 86.97% of the company’s stock.

Insiders Place Their Bets

In other Becton, Dickinson and Company news, EVP Michael David Garrison sold 1,610 shares of Becton, Dickinson and Company stock in a transaction on Thursday, January 15th. The stock was sold at an average price of $207.46, for a total transaction of $334,010.60. Following the completion of the transaction, the executive vice president directly owned 12,095 shares of the company’s stock, valued at approximately $2,509,228.70. This trade represents a 11.75% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this link. Also, Director Bertram L. Scott sold 953 shares of the company’s stock in a transaction dated Wednesday, February 18th. The stock was sold at an average price of $182.61, for a total transaction of $174,027.33. Following the completion of the sale, the director directly owned 36,763 shares in the company, valued at approximately $6,713,291.43. The trade was a 2.53% decrease in their position. The disclosure for this sale is available in the SEC filing. Over the last three months, insiders have sold 2,787 shares of company stock valued at $551,391. Company insiders own 0.40% of the company’s stock.

Becton, Dickinson and Company Stock Down 1.4%

NYSE BDX opened at $154.35 on Friday. Becton, Dickinson and Company has a 1-year low of $127.59 and a 1-year high of $187.35. The company has a market capitalization of $43.95 billion, a price-to-earnings ratio of 25.18, a PEG ratio of 11.17 and a beta of 0.24. The stock’s 50 day moving average is $185.53 and its two-hundred day moving average is $188.82. The company has a current ratio of 1.05, a quick ratio of 0.58 and a debt-to-equity ratio of 0.67.

Becton, Dickinson and Company (NYSE:BDX) last issued its earnings results on Monday, February 9th. The medical instruments supplier reported $2.91 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $2.81 by $0.10. The business had revenue of $5.25 billion during the quarter, compared to analysts’ expectations of $5.15 billion. Becton, Dickinson and Company had a return on equity of 15.76% and a net margin of 8.01%.Becton, Dickinson and Company’s quarterly revenue was up 1.6% compared to the same quarter last year. During the same period in the prior year, the firm posted $3.43 EPS. Becton, Dickinson and Company has set its FY 2026 guidance at 12.350-12.650 EPS. Equities analysts forecast that Becton, Dickinson and Company will post 14.43 earnings per share for the current fiscal year.

Becton, Dickinson and Company declared that its board has initiated a share repurchase plan on Tuesday, January 27th that permits the company to repurchase $10.00 million in shares. This repurchase authorization permits the medical instruments supplier to reacquire up to 0% of its stock through open market purchases. Stock repurchase plans are usually a sign that the company’s management believes its stock is undervalued.

Becton, Dickinson and Company Announces Dividend

The business also recently disclosed a quarterly dividend, which will be paid on Tuesday, March 31st. Shareholders of record on Tuesday, March 10th will be paid a dividend of $1.05 per share. This represents a $4.20 annualized dividend and a yield of 2.7%. The ex-dividend date is Tuesday, March 10th. Becton, Dickinson and Company’s dividend payout ratio is currently 68.52%.

Analysts Set New Price Targets

A number of analysts have commented on the company. Morgan Stanley raised their price objective on Becton, Dickinson and Company from $197.00 to $210.00 and gave the stock an “overweight” rating in a research report on Tuesday, December 2nd. Stifel Nicolaus boosted their price objective on Becton, Dickinson and Company from $210.00 to $215.00 and gave the company a “buy” rating in a research report on Wednesday, January 7th. Zacks Research lowered Becton, Dickinson and Company from a “hold” rating to a “strong sell” rating in a research note on Wednesday, February 11th. Citigroup decreased their price target on shares of Becton, Dickinson and Company from $233.00 to $232.00 and set a “buy” rating on the stock in a research note on Tuesday, February 10th. Finally, Piper Sandler reissued a “neutral” rating and issued a $170.00 price target (down from $205.00) on shares of Becton, Dickinson and Company in a report on Tuesday, February 10th. Five equities research analysts have rated the stock with a Buy rating, ten have assigned a Hold rating and one has assigned a Sell rating to the stock. According to MarketBeat.com, Becton, Dickinson and Company currently has an average rating of “Hold” and a consensus price target of $195.46.

Becton, Dickinson and Company Profile

Becton, Dickinson and Company (BDX) is a global medical technology company that develops, manufactures and sells a broad range of medical devices, instrument systems and reagents. BD’s products are used by healthcare institutions, clinical laboratories, life science researchers and the pharmaceutical industry to enable safe, effective delivery of care, specimen collection and diagnostic testing. The company’s operations span multiple business areas focused on medical devices, life sciences research tools and interventional technologies.

BD’s product portfolio includes single-use medical devices such as syringes, needles, needlesafety and injection systems, infusion therapy and medication management solutions, as well as vascular access, urology and oncology devices acquired through its interventional business.